Table 1 Differences in clinicopathological features due to intrinsic breast cancer subtypes in 327 patients
Parameters | Intrinsic subtype | P value | |||
|---|---|---|---|---|---|
Luminal (n = 108) | Luminal-HER2 (n = 42) | HER2-enriched (n = 72) | TNBC (n = 105) | ||
Age at operation | 0.054 | ||||
≤ 54 | 59 (54.6%) | 24 (57.1%) | 26 (36.1%) | 55 (52.4%) |  |
> 54 | 49 (45.4%) | 18 (42.9%) | 46 (63.9%) | 50 (47.6%) |  |
Menopause | 0.006 | ||||
Pre- | 47 (43.5%) | 22 (52.4%) | 16 (22.9%) | 36 (35.0%) | |
Post- | 61 (56.5%) | 20 (47.6%) | 54 (77.1%) | 67 (65.0%) | |
BMI | 0.341 | ||||
≤ 22.0 | 48 (44.4%) | 21 (50.0%) | 42 (58.3%) | 53 (50.5%) | |
> 22.0 | 60 (55.6%) | 21 (50.0%) | 30 (41.7%) | 52 (49.5%) | |
Tumor size | 0.528 | ||||
≤ 2 cm | 13 (12.0%) | 9 (21.4%) | 9 (12.5%) | 14 (13.3%) | |
> 2 cm | 95 (88.0%) | 33 (78.6%) | 63 (87.5%) | 91 (86.7%) | |
Lymph node status | 0.011 | ||||
Negative | 27 (25.0%) | 22 (52.4%) | 26 (36.1%) | 30 (28.6%) | |
Positive | 81 (75.0%) | 20 (47.6%) | 46 (63.9%) | 75 (71.4%) | |
TC (preNAC) | 0.632 | ||||
Normal | 52 (54.2%) | 21 (60.0%) | 39 (60.9%) | 49 (51.6%) | |
High | 44 (45.8%) | 14 (40.0%) | 25 (39.1%) | 46 (48.4%) | |
TG (preNAC) | 0.999 | ||||
Normal | 76 (79.2%) | 28 (77.8%) | 48 (78.7%) | 75 (79.0%) | |
High | 20 (20.8%) | 8 (22.2%) | 13 (21.3%) | 20 (21.0%) | |
TC (postNAC) | 0.014 | ||||
Normal | 35 (37.6%) | 15 (50.0%) | 36 (62.1%) | 33 (38.4%) | |
High | 58 (62.4%) | 15 (50.0%) | 22 (37.9%) | 53 (61.6%) | |
TG (postNAC) | 0.649 | ||||
Normal | 53 (58.9%) | 16 (55.2%) | 33 (62.3%) | 42 (51.9%) | |
High | 37 (41.1%) | 13 (44.8%) | 20 (37.7%) | 39 (48.1%) | |
Objective response rate | 0.070 | ||||
Non-ORR | 11 (10.2%) | 6 (14.3%) | 2 (2.8%) | 13 (12.4%) | |
ORR | 97 (89.8%) | 36 (85.7%) | 70 (97.2%) | 92 (87.6%) | |
Pathological response | < 0.001 | ||||
Non-pCR | 89 (82.4%) | 30 (71.4%) | 29 (40.3%) | 58 (55.2%) | |
pCR | 19 (17.6%) | 12 (28.6%) | 43 (59.7%) | 47 (44.8%) | |